Controlled release of simvastatin acid using cyclodextrin inclusion system.
Simvastatin acid (SVA) has been reported to stimulate bone formation by increasing expression of BMP-2 in osteoblasts. Due to their multi-functional characteristics and bioadaptability, cyclodextrins (CDs) are capable of forming inclusion complexes with many drugs by including a whole drug molecule inside their cavity. In the present study, we prepared SVA/CD inclusion complex solutions with different pH values. These were then used to determine their SVA release behavior after coating on titanium substrates, as well as to clarify the characteristics of SVA/CD complexes per se. Results showed that the lower the pH value of the solution, the lower the release kinetics of SVA. Besides, the amount of crystalline complexes in the coatings increased with decrease in pH. These results suggested that the release rate of SVA depended on two factors: pH of the solution and concomitant crystallinity of the coating.
Yoshinari
Masao
M
Oral Health Science Center HRC7, Tokyo Dental College, 1-2-2 Masago, Mihama-ku, Chiba 261-8502, Japan. yosinari@tdc.ac.jp
Matsuzaka
Kenichi
K
Hashimoto
Sadamitsu
S
Ishihara
Kazuyuki
K
Inoue
Takashi
T
Oda
Yutaka
Y
Ide
Takaharu
T
Tanaka
Teruo
T
D020099:Coated Materials, Biocompatible / Q000737:chemistry; D003505:Cyclodextrins / Q000737:chemistry*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D007335:Insulin-Like Growth Factor II; D011506:Proteins / Q000008:administration & dosage*; D019821:Simvastatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014025:Titanium / Q000737:chemistry
D020099:Coated Materials, Biocompatible; D003505:Cyclodextrins; D003692:Delayed-Action Preparations; C035170:IGF2 protein, human; D011506:Proteins; D007335:Insulin-Like Growth Factor II; C063287:simvastatin acid; D019821:Simvastatin; D014025:Titanium